Panobinostat (BioDeep_00000766011)
代谢物信息卡片
Panobinostat
化学式: C21H23N3O2 (349.1790178)
中文名称: 帕比司他
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO
InChI: InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XH - Histone deacetylase (hdac) inhibitors
D004791 - Enzyme Inhibitors > D056572 - Histone Deacetylase Inhibitors
C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
D000970 - Antineoplastic Agents
同义名列表
1 个代谢物同义名
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:93774
- ChEBI: CHEBI:85990
- KEGGdrug: D10319
- PubChem: 6918837
- DrugBank: DB06603
- ChEMBL: CHEMBL483254
- MeSH: Panobinostat
- CAS: 404950-80-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Zhaomei Shi, Yan Ren, Shuwei Li, Piliang Hao. Identifying drug targets with thermal proteome profiling using IBT-16plex.
Rapid communications in mass spectrometry : RCM.
2024 Jan; 38(1):e9673. doi:
10.1002/rcm.9673. [PMID: 38073198] - Marion Pardons, Basiel Cole, Laurens Lambrechts, Willem van Snippenberg, Sofie Rutsaert, Ytse Noppe, Nele De Langhe, Annemieke Dhondt, Jerel Vega, Filmon Eyassu, Erik Nijs, Ellen Van Gulck, Daniel Boden, Linos Vandekerckhove. Potent latency reversal by Tat RNA-containing nanoparticle enables multi-omic analysis of the HIV-1 reservoir.
Nature communications.
2023 Dec; 14(1):8397. doi:
10.1038/s41467-023-44020-5. [PMID: 38110433] - Dongwei Wu, Johanna Berg, Birte Arlt, Viola Röhrs, Munir A Al-Zeer, Hedwig E Deubzer, Jens Kurreck. Bioprinted Cancer Model of Neuroblastoma in a Renal Microenvironment as an Efficiently Applicable Drug Testing Platform.
International journal of molecular sciences.
2021 Dec; 23(1):. doi:
10.3390/ijms23010122. [PMID: 35008547] - Anna Skwarska, Ewen D D Calder, Deborah Sneddon, Hannah Bolland, Maria L Odyniec, Ishna N Mistry, Jennifer Martin, Lisa K Folkes, Stuart J Conway, Ester M Hammond. Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor.
Cell chemical biology.
2021 09; 28(9):1258-1270.e13. doi:
10.1016/j.chembiol.2021.04.004. [PMID: 33910023] - Morgan J Homan, Andrea Franson, Karthik Ravi, Holly Roberts, Manjunath P Pai, Cai Liu, Miao He, Aleksas Matvekas, Carl Koschmann, Bernard L Marini. Panobinostat penetrates the blood-brain barrier and achieves effective brain concentrations in a murine model.
Cancer chemotherapy and pharmacology.
2021 09; 88(3):555-562. doi:
10.1007/s00280-021-04313-2. [PMID: 34115161] - Ying-Chao Duan, Lin-Feng Jin, Hong-Mei Ren, Shao-Jie Zhang, Yue-Jiao Liu, Yong-Tao Xu, Zi-Hao He, Yu Song, Hang Yuan, Shu-Hui Chen, Yuan-Yuan Guan. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
European journal of medicinal chemistry.
2021 Aug; 220(?):113453. doi:
10.1016/j.ejmech.2021.113453. [PMID: 33957387] - Mo'tasem M Alsmadi, Nour M Al-Daoud, Mays M Jaradat, Saja B Alzughoul, Amani D Abu Kwiak, Salam S Abu Laila, Ayat J Abu Shameh, Mohammad K Alhazabreh, Sana'a A Jaber, Hala T Abu Kassab. Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment.
Biopharmaceutics & drug disposition.
2021 Jun; 42(6):263-284. doi:
10.1002/bdd.2282. [PMID: 33904202] - Yoichiro Takahashi, Akira Hayakawa, Rie Sano, Haruki Fukuda, Megumi Harada, Rieko Kubo, Takafumi Okawa, Yoshihiko Kominato. Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19.
Scientific reports.
2021 02; 11(1):3379. doi:
10.1038/s41598-021-82970-2. [PMID: 33564039] - Anthony Wood, Saby George, Nabil Adra, Sreenivasulu Chintala, Nur Damayanti, Roberto Pili. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
Investigational new drugs.
2020 08; 38(4):1108-1116. doi:
10.1007/s10637-019-00864-7. [PMID: 31654285] - Louis T Rodgers, Cynthia M Lester McCully, Arman Odabas, Rafael Cruz, Cody J Peer, William D Figg, Katherine E Warren. Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma.
Cancer chemotherapy and pharmacology.
2020 04; 85(4):827-830. doi:
10.1007/s00280-019-04021-y. [PMID: 31894347] - Jessica Perrin, Thilo Werner, Nils Kurzawa, Anna Rutkowska, Dorothee D Childs, Mathias Kalxdorf, Daniel Poeckel, Eugenia Stonehouse, Katrin Strohmer, Bianca Heller, Douglas W Thomson, Jana Krause, Isabelle Becher, H Christian Eberl, Johanna Vappiani, Daniel C Sevin, Christina E Rau, Holger Franken, Wolfgang Huber, Maria Faelth-Savitski, Mikhail M Savitski, Marcus Bantscheff, Giovanna Bergamini. Identifying drug targets in tissues and whole blood with thermal-shift profiling.
Nature biotechnology.
2020 03; 38(3):303-308. doi:
10.1038/s41587-019-0388-4. [PMID: 31959954] - Ella Willenbacher, Karin Jöhrer, Wolfgang Willenbacher, Brigitte Flögel, Richard Greil, Brigitte Kircher. Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia.
Annals of hematology.
2019 Nov; 98(11):2569-2578. doi:
10.1007/s00277-019-03797-6. [PMID: 31628518] - Vijay G Ramakrishnan, Kevin C Miller, Elaine P Macon, Teresa K Kimlinger, Jessica Haug, Sanjay Kumar, Wilson I Gonsalves, S Vincent Rajkumar, Shaji K Kumar. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
Haematologica.
2019 10; 104(10):2061-2074. doi:
10.3324/haematol.2018.211110. [PMID: 30846494] - Frédéric Anglès, Darren M Hutt, William E Balch. HDAC inhibitors rescue multiple disease-causing CFTR variants.
Human molecular genetics.
2019 06; 28(12):1982-2000. doi:
10.1093/hmg/ddz026. [PMID: 30753450] - Bumjun Kim, Caroline D Pena, Debra T Auguste. Targeted Lipid Nanoemulsions Encapsulating Epigenetic Drugs Exhibit Selective Cytotoxicity on CDH1-/FOXM1+ Triple Negative Breast Cancer Cells.
Molecular pharmaceutics.
2019 05; 16(5):1813-1826. doi:
10.1021/acs.molpharmaceut.8b01065. [PMID: 30883132] - Donald C Moore, Justin R Arnall, R Donald Harvey. Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2019 Apr; 25(3):613-622. doi:
10.1177/1078155218788706. [PMID: 30060709] - Takeshi Harada. [Role of HDAC isoforms and development of treatment of multiple myeloma using isoform-specific HDAC inhibitors].
[Rinsho ketsueki] The Japanese journal of clinical hematology.
2019; 60(9):1265-1274. doi:
10.11406/rinketsu.60.1265. [PMID: 31597852] - Lia Perez, Hugo Fernandez, Pedro Horna, Marcie Riches, Frederick Locke, Teresa Field, John Powers, Eva Sahakian, Alejandro Villagra, Asmita Mishra, Brian Betts, Mohamed Kharfan-Dabaja, Francisca Beato, Leonel Ochoa-Bayona, Joseph Pidala, Claudio Anasetti. Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease.
Bone marrow transplantation.
2018 11; 53(11):1434-1444. doi:
10.1038/s41409-018-0163-z. [PMID: 29670210] - Kazuki Okubo, Makoto Isono, Takako Asano, Akinori Sato. Panobinostat and Nelfinavir Inhibit Renal Cancer Growth by Inducing Endoplasmic Reticulum Stress.
Anticancer research.
2018 Oct; 38(10):5615-5626. doi:
10.21873/anticanres.12896. [PMID: 30275179] - Xinhui Kou, Xiaoxiao Jiang, Huijuan Liu, Xuan Wang, Fanghui Sun, Jiami Han, Jiaxing Fan, Guize Feng, Zhaohu Lin, Lan Jiang, Yonghua Yang. Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer.
Cancer science.
2018 Oct; 109(10):3272-3284. doi:
10.1111/cas.13748. [PMID: 30039622] - Chen Ai, Lei Kong. CGPS: A machine learning-based approach integrating multiple gene set analysis tools for better prioritization of biologically relevant pathways.
Journal of genetics and genomics = Yi chuan xue bao.
2018 09; 45(9):489-504. doi:
10.1016/j.jgg.2018.08.002. [PMID: 30292791] - Khumoekae Richard, David E Williams, E Dilip de Silva, Mark A Brockman, Zabrina L Brumme, Raymond J Andersen, Ian Tietjen. Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products.
Viruses.
2018 06; 10(7):. doi:
10.3390/v10070348. [PMID: 29954099] - Maria Lorenzo Pisarello, Tatyana V Masyuk, Sergio A Gradilone, Anatoliy I Masyuk, Jingyi F Ding, Pui-Yuen Lee, Nicholas F LaRusso. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
The American journal of pathology.
2018 04; 188(4):981-994. doi:
10.1016/j.ajpath.2017.12.016. [PMID: 29366679] - Benet Pera, Jan Krumsiek, Sarit E Assouline, Rossella Marullo, Jayeshkumar Patel, Jude M Phillip, Lidia Román, Koren K Mann, Leandro Cerchietti. Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway.
EBioMedicine.
2018 Feb; 28(?):80-89. doi:
10.1016/j.ebiom.2018.01.014. [PMID: 29396295] - Mathilde Van Veggel, Elsbeth Westerman, Paul Hamberg. Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat.
Clinical pharmacokinetics.
2018 01; 57(1):21-29. doi:
10.1007/s40262-017-0565-x. [PMID: 28667459] - Yukio Kobayashi, Wataru Munakata, Michinori Ogura, Toshiki Uchida, Masafumi Taniwaki, Tsutomu Kobayashi, Fumika Shimada, Masataka Yonemura, Fumiko Matsuoka, Takeshi Tajima, Kimikazu Yakushijin, Hironobu Minami. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
International journal of hematology.
2018 Jan; 107(1):83-91. doi:
10.1007/s12185-017-2327-9. [PMID: 28905323] - Janka Petravic, Thomas A Rasmussen, Sharon R Lewin, Stephen J Kent, Miles P Davenport. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
Journal of virology.
2017 05; 91(9):. doi:
10.1128/jvi.02092-16. [PMID: 28202759] - Ming Jang Chua, Megan S J Arnold, Weijun Xu, Julien Lancelot, Suzanne Lamotte, Gerald F Späth, Eric Prina, Raymond J Pierce, David P Fairlie, Tina S Skinner-Adams, Katherine T Andrews. Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth.
International journal for parasitology. Drugs and drug resistance.
2017 04; 7(1):42-50. doi:
10.1016/j.ijpddr.2016.12.005. [PMID: 28107750] - Nina H Pipalia, Kanagaraj Subramanian, Shu Mao, Harold Ralph, Darren M Hutt, Samantha M Scott, William E Balch, Frederick R Maxfield. Histone deacetylase inhibitors correct the cholesterol storage defect in most Niemann-Pick C1 mutant cells.
Journal of lipid research.
2017 04; 58(4):695-708. doi:
10.1194/jlr.m072140. [PMID: 28193631] - Zhaohu Lin, Zhuqing Zhang, Xiaoxiao Jiang, Xinhui Kou, Yong Bao, Huijuan Liu, Fanghui Sun, Shuang Ling, Ning Qin, Lan Jiang, Yonghua Yang. Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells.
Oncotarget.
2017 Mar; 8(11):17833-17848. doi:
10.18632/oncotarget.14868. [PMID: 28147319] - P S Suresh, V C Devaraj, Nuggehally R Srinivas, Ramesh Mullangi. Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.
Biomedical chromatography : BMC.
2017 Jan; 31(1):. doi:
10.1002/bmc.3807. [PMID: 27511598] - Andrea Muscat, Dean Popovski, W Samantha N Jayasekara, Fernando J Rossello, Melissa Ferguson, Kieren D Marini, Muhammad Alamgeer, Elizabeth M Algar, Peter Downie, D Neil Watkins, Jason E Cain, David M Ashley. Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2016 07; 22(14):3560-70. doi:
10.1158/1078-0432.ccr-15-2260. [PMID: 26920892] - Sarit E Assouline, Torsten Holm Nielsen, Stephen Yu, Miguel Alcaide, Lauren Chong, David MacDonald, Axel Tosikyan, Vishal Kukreti, Abbas Kezouh, Tina Petrogiannis-Haliotis, Marco Albuquerque, Daniel Fornika, Sepideh Alamouti, Remi Froment, Celia M T Greenwood, Kathleen Klein Oros, Errol Camglioglu, Ayushi Sharma, Rosa Christodoulopoulos, Caroline Rousseau, Nathalie Johnson, Michael Crump, Ryan D Morin, Koren K Mann. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.
Blood.
2016 07; 128(2):185-94. doi:
10.1182/blood-2016-02-699520. [PMID: 27166360] - Song Mu, Yoshiaki Kuroda, Hirohiko Shibayama, Masayuki Hino, Takeshi Tajima, Claudia Corrado, Rong Lin, Edward Waldron, Florence Binlich, Kenshi Suzuki. Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
European journal of clinical pharmacology.
2016 Feb; 72(2):153-61. doi:
10.1007/s00228-015-1967-z. [PMID: 26494130] - Salma Afifi, Angela Michael, Mahshid Azimi, Mabel Rodriguez, Nikoletta Lendvai, Ola Landgren. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.
Pharmacotherapy.
2015 Dec; 35(12):1173-88. doi:
10.1002/phar.1671. [PMID: 26684557] - Anne Sofie Høgh Kølbæk Kjær, Christel Rothe Brinkmann, Charles A Dinarello, Rikke Olesen, Lars Østergaard, Ole Schmeltz Søgaard, Martin Tolstrup, Thomas Aagaard Rasmussen. The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients.
AIDS (London, England).
2015 Jun; 29(10):1195-200. doi:
10.1097/qad.0000000000000678. [PMID: 25870990] - Marina Savelieva, Margaret M Woo, Horst Schran, Song Mu, Jerry Nedelman, Renaud Capdeville. Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors.
European journal of clinical pharmacology.
2015 Jun; 71(6):663-672. doi:
10.1007/s00228-015-1846-7. [PMID: 25939707] - Michaela Waibel, Ailsa J Christiansen, Margaret L Hibbs, Jake Shortt, Sarah A Jones, Ian Simpson, Amanda Light, Kristy O'Donnell, Eric F Morand, David M Tarlinton, Ricky W Johnstone, Edwin D Hawkins. Manipulation of B-cell responses with histone deacetylase inhibitors.
Nature communications.
2015 Apr; 6(?):6838. doi:
10.1038/ncomms7838. [PMID: 25913720] - Kang Lu, Xiao-sheng Fang, Li-li Feng, Yu-jie Jiang, Xiang-xiang Zhou, Xin Liu, Pei-pei Li, Na Chen, Mei Ding, Na Wang, Jie Zhang, Xin Wang. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
Cancer letters.
2015 Apr; 359(2):250-8. doi:
10.1016/j.canlet.2015.01.021. [PMID: 25636517] - Tao Yan-Fang, Li Zhi-Heng, Xu Li-Xiao, Fang Fang, Lu Jun, Li Gang, Cao Lan, Wang Na-Na, Du Xiao-Juan, Sun Li-Chao, Zhao Wen-Li, Xiao Pei-Fang, Zhao He, Su Guang-Hao, Li Yan-Hong, Li Yi-Ping, Xu Yun-Yun, Zhou Hui-Ting, Wu Yi, Jin Mei-Fang, Liu Lin, Ni Jian, Hu Shao-Yan, Zhu Xue-Ming, Feng Xing, Wang Jian, Pan Jian. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
PloS one.
2015; 10(7):e0126566. doi:
10.1371/journal.pone.0126566. [PMID: 26176219] - Sunil Sharma, Petronella O Witteveen, Martijn P Lolkema, Dagmar Hess, Hans Gelderblom, Syed A Hussain, Maria G Porro, Edward Waldron, Sue-Zette Valera, Song Mu. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
Cancer chemotherapy and pharmacology.
2015 Jan; 75(1):87-95. doi:
10.1007/s00280-014-2612-8. [PMID: 25377157] - Marije Slingerland, Dagmar Hess, Sally Clive, Sunil Sharma, Per Sandstrom, Niklas Loman, Maria G Porro, Song Mu, Edward Waldron, Sue-Zette Valera, Hans Gelderblom. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
Cancer chemotherapy and pharmacology.
2014 Nov; 74(5):1089-98. doi:
10.1007/s00280-014-2594-6. [PMID: 25253045] - Akinori Sato, Takako Asano, Makoto Isono, Keiichi Ito, Tomohiko Asano. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
BMC urology.
2014 Aug; 14(?):71. doi:
10.1186/1471-2490-14-71. [PMID: 25176354] - Y Oki, D Buglio, J Zhang, Y Ying, S Zhou, A Sureda, D Ben-Yehuda, P L Zinzani, H M Prince, S J Harrison, M Kirschbaum, P B Johnston, A Shen, B von Tresckow, A Younes. Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression.
Blood cancer journal.
2014 Aug; 4(?):e236. doi:
10.1038/bcj.2014.58. [PMID: 25105535] - Yasuhiro Oki, Daniela Buglio, Michelle Fanale, Luis Fayad, Amanda Copeland, Jorge Romaguera, Larry W Kwak, Barbara Pro, Silvana de Castro Faria, Sattva Neelapu, Nathan Fowler, Fredrick Hagemeister, Jiexin Zhang, Shouhao Zhou, Lei Feng, Anas Younes. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2013 Dec; 19(24):6882-90. doi:
10.1158/1078-0432.ccr-13-1906. [PMID: 24097867] - Ronald Feld, Margaret M Woo, Natasha Leighl, Frances A Shepherd, J Thaddeus Beck, Lihui Zhao, Lucien Gazi, Thomas Hengelage, Maria Grazia Porro, Asha Nayak. A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer.
Cancer chemotherapy and pharmacology.
2013 Oct; 72(4):747-55. doi:
10.1007/s00280-013-2237-3. [PMID: 24013574] - Miqing Xu, Ming Hong, Hui Xie. Histone deacetylase inhibitors induce human renal cell carcinoma cell apoptosis through p-JNK activation.
Nan fang yi ke da xue xue bao = Journal of Southern Medical University.
2013 Oct; 33(10):1409-15. doi:
NULL. [PMID: 24144737] - F Lai, S T Guo, L Jin, C C Jiang, C Y Wang, A Croft, M N Chi, H-Y Tseng, M Farrelly, B Atmadibrata, J Norman, T Liu, P Hersey, X D Zhang. Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.
Cell death & disease.
2013 Jun; 4(?):e655. doi:
10.1038/cddis.2013.192. [PMID: 23744355] - Michele Cea, Antonia Cagnetta, Marco Gobbi, Franco Patrone, Paul G Richardson, Teru Hideshima, Kenneth C Anderson. New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
Current pharmaceutical design.
2013; 19(4):734-44. doi:
NULL. [PMID: 23016853] - Sally Clive, Margaret M Woo, Thomas Nydam, Lindsay Kelly, Margaret Squier, Mark Kagan. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients.
Cancer chemotherapy and pharmacology.
2012 Oct; 70(4):513-22. doi:
10.1007/s00280-012-1940-9. [PMID: 22864948] - Sachi Morita, Satoshi Oizumi, Hironobu Minami, Koichi Kitagawa, Yoshito Komatsu, Yutaka Fujiwara, Megumi Inada, Satoshi Yuki, Naomi Kiyota, Ayako Mitsuma, Masataka Sawaki, Hiromi Tanii, Junko Kimura, Yuichi Ando. Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors.
Investigational new drugs.
2012 Oct; 30(5):1950-7. doi:
10.1007/s10637-011-9751-0. [PMID: 21964801] - Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio Anasetti, Xue-Zhong Yu. LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2012 Aug; 18(8):1182-1190.e1. doi:
10.1016/j.bbmt.2012.06.002. [PMID: 22698484] - Paola Neri, Nizar J Bahlis, Sagar Lonial. Panobinostat for the treatment of multiple myeloma.
Expert opinion on investigational drugs.
2012 May; 21(5):733-47. doi:
10.1517/13543784.2012.668883. [PMID: 22404247] - Jessica E S Bohonowych, Shuping Peng, Udhayakumar Gopal, Michael W Hance, Shane B Wing, Kelley M Argraves, Karen Lundgren, Jennifer S Isaacs. Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation.
BMC cancer.
2011 Dec; 11(?):520. doi:
10.1186/1471-2407-11-520. [PMID: 22172030] - A Estella-Hermoso de Mendoza, I Imbuluzqueta, M A Campanero, D Gonzalez, A Vilas-Zornoza, X Agirre, H Lana, G Abizanda, F Prosper, M J Blanco-Prieto. Development and validation of ultra high performance liquid chromatography-mass spectrometry method for LBH589 in mouse plasma and tissues.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2011 Nov; 879(30):3490-6. doi:
10.1016/j.jchromb.2011.09.029. [PMID: 21983199] - A Sacco, I M Ghobrial, A M Roccaro. Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia.
Current cancer drug targets.
2011 Nov; 11(9):1025-9. doi:
10.2174/156800911798073032. [PMID: 21933107] - Paul Hamberg, Margaret M Woo, Lin-Chi Chen, Jaap Verweij, Maria Grazia Porro, Lily Zhao, Wenkui Li, Diane van der Biessen, Sunil Sharma, Thomas Hengelage, Maja de Jonge. Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
Cancer chemotherapy and pharmacology.
2011 Sep; 68(3):805-13. doi:
10.1007/s00280-011-1693-x. [PMID: 21706316] - John D Hainsworth, Jeffrey R Infante, David R Spigel, Edward R Arrowsmith, Ralph V Boccia, Howard A Burris. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma.
Cancer investigation.
2011 Aug; 29(7):451-5. doi:
10.3109/07357907.2011.590568. [PMID: 21696296] - Piergiorgio Pettazzoni, Stefania Pizzimenti, Cristina Toaldo, Paula Sotomayor, Luigina Tagliavacca, Song Liu, Dan Wang, Rosalba Minelli, Leigh Ellis, Peter Atadja, Eric Ciamporcero, Mario Umberto Dianzani, Giuseppina Barrera, Roberto Pili. Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells.
Free radical biology & medicine.
2011 Jan; 50(2):313-22. doi:
10.1016/j.freeradbiomed.2010.11.011. [PMID: 21078383] - Antonia Kalushkova, Mårten Fryknäs, Miguel Lemaire, Charlotte Fristedt, Prasoon Agarwal, Maria Eriksson, Sarah Deleu, Peter Atadja, Anders Osterborg, Kenneth Nilsson, Karin Vanderkerken, Fredrik Oberg, Helena Jernberg-Wiklund. Polycomb target genes are silenced in multiple myeloma.
PloS one.
2010 Jul; 5(7):e11483. doi:
10.1371/journal.pone.0011483. [PMID: 20634887] - Enrique M Ocio, David Vilanova, Peter Atadja, Patricia Maiso, Edvan Crusoe, Diego Fernández-Lázaro, Mercedes Garayoa, Laura San-Segundo, Teresa Hernández-Iglesias, Enrique de Alava, Wenlin Shao, Yung-Mae Yao, Atanasio Pandiella, Jesús F San-Miguel. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
Haematologica.
2010 May; 95(5):794-803. doi:
10.3324/haematol.2009.015495. [PMID: 19951978] - Elke De Bruyne, Tomas J Bos, Frans Schuit, Els Van Valckenborgh, Eline Menu, Lieven Thorrez, Peter Atadja, Helena Jernberg-Wiklund, Karin Vanderkerken. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms.
Blood.
2010 Mar; 115(12):2430-40. doi:
10.1182/blood-2009-07-232801. [PMID: 20086250] - Stefan Schmitt, Anthony D Ho, Hartmut Goldschmidt. The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.
Onkologie.
2010; 33(4):183-6. doi:
10.1159/000286447. [PMID: 20389145] - Tai-Lung Cha, Mei-Jen Chuang, Sheng-Tang Wu, Guang-Huan Sun, Sun-Yran Chang, Dah-Shyong Yu, Shih-Ming Huang, Steven Kuan-Hua Huan, Tse-Chou Cheng, Tzu-Ting Chen, Pao-Luo Fan, Pei-Wen Hsiao. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2009 Feb; 15(3):840-50. doi:
10.1158/1078-0432.ccr-08-1918. [PMID: 19188154] - Elke De Bruyne, Tomas Jan Bos, Kewal Asosingh, Isabelle Vande Broek, Eline Menu, Els Van Valckenborgh, Peter Atadja, Valérie Coiteux, Xavier Leleu, Kris Thielemans, Ben Van Camp, Karin Vanderkerken, Ivan Van Riet. Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2008 May; 14(10):2918-26. doi:
10.1158/1078-0432.ccr-07-4489. [PMID: 18483358] - Francis Giles, Thomas Fischer, Jorge Cortes, Guillermo Garcia-Manero, Joachim Beck, Farhad Ravandi, Eric Masson, Patricia Rae, Glen Laird, Sunil Sharma, Hagop Kantarjian, Margaret Dugan, Maher Albitar, Kapil Bhalla. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2006 Aug; 12(15):4628-35. doi:
10.1158/1078-0432.ccr-06-0511. [PMID: 16899611]